A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Recruiting
HealthQuest Pharma Inc.
Phase 1
This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2
Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or
Other Solid Tumors.
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Recruiting
Ascentage Pharma Group Inc.
Phase 1
This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2
Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or
Other Solid Tumors.
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
Completed
HealthQuest Pharma Inc.
Phase 1
The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants
with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and
fasting meals separately（Selection of high-fat meal spectrum：《The Food - Effect
Bioavailability and Fed Bioequivalence Studies》high fat diet should be 800-1000 kcal heat.).
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
Completed
Ascentage Pharma Group Inc.
Phase 1
The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants
with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and
fasting meals separately（Selection of high-fat meal spectrum：《The Food - Effect
Bioavailability and Fed Bioequivalence Studies》high fat diet should be 800-1000 kcal heat.).
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
Active, not recruiting
Ascentage Pharma Group Inc.
Phase 2
The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic
myeloid leukemia in chronic phase (CML-CP) harboring T315I mutation. The efficacy of HQP1351
was determined by evaluating the subjects' major cytogenetic response (MCyR).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
